Targeting Nav1.8 with specific inhibitors might provide a potential novel approach in the future in antiarrhythmic drug therapy, because recent studies have found that Nav1.8 expression is significantly up-regulated in human left ventricular hypertrophy (Ahmad et al., 2019) and HF (Dybkova et al., 2018). This evidence concerns the gene SCN10A and left ventricular hypertrophy.